Should all young cancer patients get genetic testing? study investigates

NCT ID NCT04533555

Completed Knowledge-focused Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing based on doctor's judgment. The goal was to see which approach finds more inherited genetic risks that could affect patients and their families.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: broad gene panel for young adult cancers
What this could lead to: If successful, this could lead to a simpler, more effective way to identify genetic risks in young cancer patients and their families.
What could go wrong: This is a completed study comparing testing strategies, not a treatment trial. Results may not change current practice if universal testing proves too costly or impractical.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.